Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

OGEN opened at $0.33 on Friday. The company has a market capitalization of $1.82 million, a PE ratio of -0.04 and a beta of 0.45. Oragenics has a fifty-two week low of $0.29 and a fifty-two week high of $7.74. The business has a 50-day moving average of $0.72 and a 200-day moving average of $1.14.

Oragenics (NYSE:OGEN – Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.51) EPS for the quarter.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the SEC. 18.71% of the stock is currently owned by hedge funds and other institutional investors.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Recommended Stories